April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
KEYNOTE-826 Data Confirm Survival Benefit of Pembrolizumab Addition in Cervical Cancer
June 16th 2023In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.
Read More
Chemoradiation Alone Remains Best Treatment for Locally Advanced Cervical Cancer
May 6th 2023Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.
Read More
Ceralasertib Shows Clinical Activity With or Without Olaparib in Gynecologic Cancers
April 27th 2023Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.
Read More
HRD Mutations Propel New Approaches in Uterine Cancer
April 25th 2023Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.
Read More
Atezolizumab Before/Concurrent With CRT Enhances Immunogenicity in Cervical Cancer
March 29th 2023At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.
Read More
Long-Term Follow-Up Shows Olaparib’s Efficacy in Ovarian Cancer
January 20th 2023During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.
Read More
Available Systemic Therapy Options for Patients with MMR-Proficient Metastatic Endometrial Cancer
January 19th 2023An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.
Watch
Phase 1 Study Shows Signals of Response With Vaccine for HPV16+ Premalignancies
December 1st 2022In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.
Read More
Salani Reviews Role of PARP Inhibition in Ovarian Cancer
November 24th 2022During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.
Read More
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
November 14th 2022Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
Read More